3 views on Virtus
3 views on Virtus. After a strong IPO in 2013 the Virtus Health share price has had challenging period post their interim result. Morgans Life Sciences analyst Scott Power sees recent share price weakness as a buying opportunity, suggesting the market is overplaying perceived growth headwinds. Power says, we see further upside from a move into an overseas region which would likely re-invigorate interest in this name. This view is echoed by Don Williams, CIO of Platypus. We believe the market has forgotten about some of the growth options for Virtus. We think it is likely that they will acquire something overseas and that the local growth prospects are good enough to justify the valuation. Power currently has a price target of $8.94 for Virtus (currently trading at $7.50). Livewire spoke with Virtus CEO, Ms Susan Channon a few weeks ago. Watch the video here:
&feature=youtu.be&t=3m2s